既往生物制剂作用机制对IBD抗TNF疗效的影响:ENEIDA登记研究
基于ENEIDA登记的多中心研究,评估不同作用机制生物制剂后二线抗TNF治疗的持久性。结果显示,在克罗恩病中,不同机制后抗TNF较一线抗TNF停药风险更高(HR 1.55);在溃疡性结肠炎中,不同机制后抗TNF较一线抗TNF及抗TNF后抗TNF持久性均更低(HR 1.69和1.91),且缓解率显著更低。
要点
- 克罗恩病中,不同机制后抗TNF较一线抗TNF停药风险增高(HR 1.55),疗效无显著差异。
- 溃疡性结肠炎中,不同机制后抗TNF较一线抗TNF持久性更低(HR 1.69)。
- 溃疡性结肠炎中,不同机制后抗TNF较抗TNF后抗TNF持久性更低(HR 1.91),缓解率显著更低。
核心结论
- 不同作用机制生物制剂后使用抗TNF治疗与疗效和持久性降低相关,尤其在溃疡性结肠炎中。
主要发现
- 克罗恩病中,不同机制后抗TNF(62%乌司奴单抗)较一线抗TNF停药风险更高(HR 1.55;95%CI 1.05-2.30),短期或长期临床疗效无显著差异。
- 溃疡性结肠炎中,不同机制后抗TNF(90%维得利珠单抗)较一线抗TNF持久性更低(HR 1.69;95%CI 1.31-2.19),较抗TNF后抗TNF持久性更低(HR 1.91;95%CI 1.48-2.48)。
- 溃疡性结肠炎中,不同机制后抗TNF的短期和长期缓解率均显著更低(p < 0.001)。
临床怎么用
- 在溃疡性结肠炎中,选择抗TNF作为不同机制生物制剂后的二线治疗需谨慎评估其持久性和缓解率可能降低。
- 克罗恩病中,不同机制后抗TNF虽停药风险增高,但短期和长期临床疗效与一线抗TNF无显著差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The expanding use of targeted therapies in inflammatory bowel disease has made treatment sequencing increasingly relevant, yet evidence on anti-TNF effectiveness after prior biologics with different mechanisms of action (MOA) remains limited. Our objective is to evaluate the durability of anti-TNF treatment in this scenario. METHODS: Multicentre study based on data from the ENEIDA registry. Patients who received second-line anti-TNF therapy after a first biologic with a different MOA for active luminal disease were identified. Using propensity score matching, each case was matched with three controls from two cohorts: patients treated with second-line anti-TNF after another anti-TNF and patients receiving first-line anti-TNF therapy. Treatment durability and short- and long-term clinical effectiveness were assessed. RESULTS: Sixty-six Crohn's disease patients and 117 UC patients receiving anti-TNF after other MOA were included. In CD, second-line anti-TNF therapy after a different MOA (62% ustekinumab) was associated with a higher risk of treatment discontinuation compared with first-line anti-TNF therapy (HR 1.55; 95% CI, 1.05-2.30), without significant differences in short- or long-term clinical effectiveness. In UC, anti-TNF therapy after a different MOA (90% vedolizumab) was associated with lower treatment durability compared with first-line anti-TNF therapy (HR 1.69; 95% CI, 1.31-2.19) and with anti-TNF after another anti-TNF agent (HR 1.91; 95% CI, 1.48-2.48), its remission rates significantly lower at both short- and long-term follow-up (p < 0.001). CONCLUSIONS: Anti-TNF therapy used after a different MOA is associated with reduced effectiveness and durability compared with its use as first-line therapy or after another anti-TNF agent, especially in UC.
引用
- Yagüe Caballero C, García López S, Royo Esteban A, et al. Impact of Prior Biologic Mechanism of Action on Anti-TNF Effectiveness in Inflammatory Bowel Disease: An ENEIDA Registry Study. Aliment Pharmacol Ther. 2026. PMID: 42581715. doi:10.1111/apt.70904
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。